Background Experimental and clinical evidence supports the role of inflammation in
atherosclerosis and its complications. Colchicine is an orally administered, potent …

Background Following an acute myocardial infarction (MI), patients with persistently
elevated biomarkers of inflammation, in particular C-reactive protein (CRP), are at …

Background: Inflammation plays a crucial role in clinical manifestations and complications of
acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has …

Background Evidence from a recent trial has shown that the antiinflammatory effects of
colchicine reduce the risk of cardiovascular events in patients with recent myocardial …

Aims Recent randomized trials demonstrated a benefit of low-dose colchicine added to
guideline-based treatment in patients with recent myocardial infarction or chronic coronary …

Aims In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial
(COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose …

Abstract Aims The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the
benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine …

Background Inflammation plays a pivotal role in coronary artery disease (CAD). The anti‐
inflammatory drug colchicine seems to reduce ischemic events in patients with CAD. So far …

Colchicine is an ancient drug, traditionally used for the treatment and prevention of gouty
attacks; it has become standard of treatment for pericarditis with a potential role in the …

Background Reduction of inflammation with colchicine has emerged as a therapeutic option
for secondary prevention of cardiovascular disease (CVD) in patients with coronary artery …